1. National Institute of Mental Health. Reference links: 1, 2

2. Kessler RC et al. (2003). The Epidemiology of Major Depressive Disorder. Results From the National Comorbidity Survey Replication (NCS-R). JAMA, 289(23):3095-3105. Article link

3. Kito, S, et al. (2008). Changes in Regional Blood Flow After Repetitive Transcranial Magnetic Stimulation of the Left Dorsolateral Prefrontal Cortex in Treatment-Resistant Depression. Journal of Neurosciences, 20: 74-80. Article link

4. Rush AJ, et. al. (2006). Acute and Longer-term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: a STAR*D Report. Am J Psychiatry, 163(11):1905-1917. Article link

5. Fava M, et. al. (2006). A Comparison of Mirtazapine and Nortriptyline Following Two Consecutive Failed Medication Treatments for Depressed Outpatients: A Star*D Report. Am J Psychiatry, 163(7):1161-1172. Article link

6. McGrath PJ, et al. (2006). Tranylcypromine Versus Venlafaxine Plus Mirtazapine Following Three Failed Antidepressant Medication Trials for Depression: A STAR*D Report. Am J Psychiatry, 163(9):1531-1541. Article link

7. NeuroStar Prescribing Information. Reference link

8. Janicak PG, et al. (2008). Transcranial Magnetic Stimulation in the Treatment of Major Depressive Disorder: A Comprehensive Summary of Safety Experience from Acute Exposure, Extended Exposure, and During Reintroduction Treatment. J Clin Psychiatry, 69(2):222-232. Article link

9. Dunner DL, et al. (2014). A Multisite, Naturalistic, Observational Study of Transcranial Magnetic Stimulation (TMS) for Patients with Pharmacoresistant Major Depressive Disorder: Durability of Benefit Over a 1-Year Follow-Up Period. J Clin Psychiatry, 75(12): 1394-401. Article link

10. Kessler, RC et al. (2005). Lifetime Prevalence and Age-of-Onset Distributions of DSM-IV Disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry, 62(6):593-602. Article link

11. Carpenter LL, et al. (2012). Transcranial Magnetic Stimulation (TMS) for Major Depression: A Multisite, Naturalistic, Observational Study of Acute Treatment Outcomes in Clinical Practice. Depression and Anxiety, 29(7):587-596. Article link

12. George MS, et al. (2010). Daily Left Prefrontal Transcranial Magnetic Stimulation Therapy for Major Depressive Disorder: A Sham-Controlled Randomized Trial. Arch Gen Psychiatry, 67(5):507-516. Article link

13. O’Reardon JP, et al. (2007). Efficacy and Safety of Transcranial Magnetic Stimulation in the Acute Treatment of Major Depression: A Multisite Randomized Controlled Trial. Biol Psychiatry, 62(11):1208-1216. Article link

14. Janicak PG, et al. (2010). Durability of Clinical Benefit with Transcranial Magnetic Stimulation (TMS) in the Treatment of Pharmacoresistant Major Depression: Assessment of Relapse During a 6-Month, Multisite, Open-Label Study. Brain Stimulation, 3(4):187-199. Article link

15. Gelenberg AJ, et al. (2010). Practice Guidelines for the Treatment of Patients with Major Depressive Disorder, American Psychiatric Association, 3rd Edition. Reference link

16. Neuronetics, Inc. Data on file. Reference link

17. Demitrack MA, Thase, ME. (2009). Clinical Significance of Transcranial Magnetic Stimulation (TMS) in the Treatment of Pharmacoresistant Depression: Synthesis of Recent Data. Psychopharm Bull, 42(2): 5-38. Article link

18. Strehl U, et al. (2017). Neurofeedback of Slow Cortical Potentials in Children with Attention-Deficit/Hyperactivity Disorder (ADHD): A Multicenter Randomized Trial Controlling for Unspecific Effects. Front Hum Neurosci, 11:135. Article link

19. Jessica Van Doren et al. (2018). Sustained Effects of Neurofeedback in ADHD: A Systematic Review and Meta Analysis. Eur Child Adolesc Psychiatry, 28(3): 293-305. Article link

20. Arns et al. (2012). The Effects of QEEG-Informed Neurofeedback in ADHD: An Open-Label Pilot Study. Appl Psychophysiol Biofeedback, 37(3): 171-80. Article link

21. George, Mark. (1993). A PET scan measures vital functions such as blood flow, oxygen use and blood sugar (glucose) metabolism. Biological Psychiatry Branch Division of Intramural Research Program, NIMH.

22. Centers for Disease Control and Prevention Reference links: 1, 2, 3

23. Food and Drug Administration Reference link

24. Greenberg, PE, et al. (2003). The Economic Burden of Depressive Disorders in the United States: How Did It Change Between 1990 and 2000? Journal of Clinical Psychiatry, 64 (12): 1465-1475. Article link

25. Murray CJ, Lopez AD. (1996). Evidence-based Health Policy – Lessons from the Global Burden of Disease Study. Science, 274 (5288): 740-743. Article link

26. Heron, Melonie, et al. (2009). Deaths: Final Data for 2006. Natl Vital Stat Rep, 57(14): 1-134. Article link

27. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 5th edition. Arlington, VA., American Psychiatric Association, 2013. Reference link

28. Cleveland Clinic: Mood DisordersReference link

29. Mayo Clinic: OCD. Reference link

30. Johns Hopkins Medicine: OCDReference link

31. The Clinical TMS Society: Recommended OCD Coverage Policy. Reference link

32. National Institute of Mental Health. Anxiety Disorders. Reference link

33. Zhao, Ke, et al. (2017). Cortical thickness and subcortical structure volume abnormalities in patients with major depression with and without anxious symptoms. Brain Behav. 2017 Aug; 7(8): e00754. Article link

34. Martin, Elizabeth I., et al. (2013). The Neurobiology of Anxiety Disorders: Brain Imaging, Genetics, and Psychoneuroendocrinology. Psychiatr Clin North Am. 2009 Sep; 32(3): 549–575. Article link 

35. EMPR. TMS Device NeuroStar Cleared for Anxious Depression. Article link 

36. Mayo Clinic. Anxiety Disorders. Reference link